RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+1.05%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$6.63B
AUM Growth
+$6.63B
(-7.3%)
Cap. Flow
-$82.7M
Cap. Flow
% of AUM
-1.25%
Top 10 Holdings %
Top 10 Hldgs %
50.25%
Holding
100
New
18
Increased
9
Reduced
13
Closed
18
Top Buys
| 1 |
Vor Biopharma
VOR
|
$479M |
| 2 |
Instil Bio
TIL
|
$122M |
| 3 |
Edgewise Therapeutics
EWTX
|
$84.9M |
| 4 |
Bolt Biotherapeutics
BOLT
|
$78.3M |
| 5 |
Seres Therapeutics
MCRB
|
$76.1M |
Top Sells
| 1 |
Arvinas
ARVN
|
$312M |
| 2 |
TG Therapeutics
TGTX
|
$195M |
| 3 |
Novavax
NVAX
|
$143M |
| 4 |
Keros Therapeutics
KROS
|
$132M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$72.9M |
Sector Composition
| 1 | Healthcare | 95.53% |
| 2 | Financials | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $826M | 12.46% | 6,412,228 +546,890 | +9% | +$70.5M |
|
|
2
Novavax
NVAX
$1.21B
| $544M | 8.21% | 3,002,087 -786,477 | -21% | -$143M |
|
|
3
Vor Biopharma
VOR
$250M
| $479M | 7.23% | +11,120,973 | New | +$479M |
|
4
Atea Pharmaceuticals
AVIR
$267M
| $332M | 5% | 5,368,451 | – | – |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $253M | 3.81% | 9,011,651 | – | – |
|
|
6
TG Therapeutics
TGTX
$4.65B
| $223M | 3.37% | 4,636,146 -4,049,325 | -47% | -$195M |
|
7
Nkarta
NKTX
$151M
| $184M | 2.78% | 5,605,129 | – | – |
|
|
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
| $182M | 2.75% | 3,556,810 -1,219,738 | -26% | -$62.5M |
|
9
MacroGenics
MGNX
$112M
| $157M | 2.37% | 4,933,594 +558,377 | +13% | +$17.8M |
|
10
iTeos Therapeutics
ITOS
| $151M | 2.28% | 4,417,258 | – | – |
|
|
IMGN
11
DELISTED
Immunogen Inc
IMGN
| $149M | 2.25% | 18,417,458 | – | – |
|
12
Travere Therapeutics
TVTX
$1.56B
| $140M | 2.11% | 5,614,428 +1,056,561 | +23% | +$26.4M |
|
|
13
Instil Bio
TIL
$182M
| $122M | 1.84% | +4,870,793 | New | +$122M |
|
14
Phathom Pharmaceuticals
PHAT
$864M
| $117M | 1.76% | 3,115,008 -710,000 | -19% | -$26.7M |
|
15
89bio
ETNB
$1.34B
| $112M | 1.69% | 4,736,214 | – | – |
|
|
KNTE
16
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $112M | 1.69% | 3,593,052 | – | – |
|
17
Rhythm Pharmaceuticals
RYTM
$6.85B
| $104M | 1.56% | 4,871,067 +692,000 | +17% | +$14.7M |
|
|
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
| $103M | 1.56% | 5,283,976 -61,655 | -1% | -$1.2M |
|
19
Axsome Therapeutics
AXSM
$6.05B
| $93.7M | 1.41% | 1,655,447 | – | – |
|
20
Rocket Pharmaceuticals
RCKT
$354M
| $93.5M | 1.41% | 2,107,149 -28,932 | -1% | -$1.28M |
|
21
Adverum Biotechnologies
ADVM
$64.6M
| $92.3M | 1.39% | 9,365,833 -136,550 | -1% | -$1.35M |
|
|
22
Edgewise Therapeutics
EWTX
$1.51B
| $84.9M | 1.28% | +2,613,623 | New | +$84.9M |
|
23
Curis
CRIS
$20.9M
| $80.8M | 1.22% | 7,140,091 -567,699 | -7% | -$6.43M |
|
|
24
Bolt Biotherapeutics
BOLT
$9.85M
| $78.3M | 1.18% | +2,378,325 | New | +$78.3M |
|
25
Vaxcyte
PCVX
$4B
| $76.4M | 1.15% | 3,865,808 +155,109 | +4% | +$3.06M |
|